When attending a botulinum toxin appointment, patients should inform their practitioner that they are taking Ozempic, including details about: The dose and duration of Ozempic treatment Any recent dose changes or titration schedule Current side effects, particularly nausea, vomiting, or gastrointestinal symptoms Whether weight loss has occurred and the approximate amount Use of insulin or sulfonylureas, as these combined with Ozempic increase hypoglycaemia risk [1] [2] Any history of diabetic retinopathy or current ophthalmology care Any other medications, including over-the-counter products and supplements Pregnancy status or plans to conceive (semaglutide is contraindicated in pregnancy and should be discontinued at least 2 months before planned conception) [1] [2] Similarly, when discussing Ozempic with a GP or diabetes specialist, patients should mention if they receive regular botulinum toxin treatments

Your dose may need to go up, but your price won't, eliminating cost barriers to reaching your therapeutic level
Mounjaro is administered as a once-weekly subcutaneous injection, with treatment starting at 2.5 mg for 4 weeks as an initiation dose (not intended for glycaemic control)
Further to this, early preclinical work with dual GIP/GLP-2 hybrid analogues demonstrates considerable therapeutic promise
Incretin-based Therapies for Type 2 Diabetes Mellitus: Focus on Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors